258 related articles for article (PubMed ID: 22991313)
1. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.
Andrews EB; Gilsenan AW; Midkiff K; Sherrill B; Wu Y; Mann BH; Masica D
J Bone Miner Res; 2012 Dec; 27(12):2429-37. PubMed ID: 22991313
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study.
Gilsenan A; Midkiff K; Harris D; Kellier-Steele N; McSorley D; Andrews EB
J Bone Miner Res; 2021 Feb; 36(2):244-251. PubMed ID: 32990990
[TBL] [Abstract][Full Text] [Related]
3. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years.
Gilsenan A; Harding A; Kellier-Steele N; Harris D; Midkiff K; Andrews E
Osteoporos Int; 2018 Oct; 29(10):2335-2343. PubMed ID: 29978254
[TBL] [Abstract][Full Text] [Related]
4. Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma.
Andrews EB; Gilsenan A; Midkiff K; Harris D
Ann Epidemiol; 2016 Nov; 26(11):751-753. PubMed ID: 27645108
[No Abstract] [Full Text] [Related]
5. Safety of parathyroid hormone for the treatment of osteoporosis.
Miller PD
Curr Osteoporos Rep; 2008 Mar; 6(1):12-6. PubMed ID: 18430395
[TBL] [Abstract][Full Text] [Related]
6. Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes.
Kellier-Steele N; Casso D; Anderson A; Oliveria SA; Motsko S
Bone; 2022 Jul; 160():116394. PubMed ID: 35318162
[TBL] [Abstract][Full Text] [Related]
7. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data.
Gilsenan A; Midkiff K; Harris D; McQuay L; Hunter S; Kellier-Steele N; Andrews E
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1616-1626. PubMed ID: 32894794
[TBL] [Abstract][Full Text] [Related]
8. Of mice and men: divergent risks of teriparatide-induced osteosarcoma.
Subbiah V; Madsen VS; Raymond AK; Benjamin RS; Ludwig JA
Osteoporos Int; 2010 Jun; 21(6):1041-5. PubMed ID: 19597911
[TBL] [Abstract][Full Text] [Related]
9. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study.
Gilsenan A; Harris D; Reynolds M; McSorley D; Midkiff K; Jackson L; Muldavin B; Kellier-Steele N; Andrews E
Osteoporos Int; 2021 Apr; 32(4):645-651. PubMed ID: 33151378
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human parathyroid hormone. Preclinical data on rat osteosarcoma were not dismissed.
Kuijpers G; Schneider B; Stadel B; Colman E
BMJ; 2002 May; 324(7347):1218; author reply 1218. PubMed ID: 12016199
[No Abstract] [Full Text] [Related]
11. Initial experience with teriparatide in the United States.
Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
[TBL] [Abstract][Full Text] [Related]
12. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
Orwoll ES; Scheele WH; Paul S; Adami S; Syversen U; Diez-Perez A; Kaufman JM; Clancy AD; Gaich GA
J Bone Miner Res; 2003 Jan; 18(1):9-17. PubMed ID: 12510800
[TBL] [Abstract][Full Text] [Related]
13. Probable osteosarcoma risk after prolonged teriparatide treatment: comment on the article by Saag et al.
Tastekin N; Zateri C
Arthritis Rheum; 2010 Jun; 62(6):1837; author reply 1837-8. PubMed ID: 20191586
[No Abstract] [Full Text] [Related]
14. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)).
Watanabe A; Yoneyama S; Nakajima M; Sato N; Takao-Kawabata R; Isogai Y; Sakurai-Tanikawa A; Higuchi K; Shimoi A; Yamatoya H; Yoshida K; Kohira T
J Toxicol Sci; 2012; 37(3):617-29. PubMed ID: 22688001
[TBL] [Abstract][Full Text] [Related]
15. Safety of osteoanabolic therapy: a decade of experience.
Cipriani C; Irani D; Bilezikian JP
J Bone Miner Res; 2012 Dec; 27(12):2419-28. PubMed ID: 23165426
[No Abstract] [Full Text] [Related]
16. The experience of accommodating privacy restrictions during implementation of a large-scale surveillance study of an osteoporosis medication.
Midkiff KD; Andrews EB; Gilsenan AW; Deapen DM; Harris DH; Schymura MJ; Hornicek FJ
Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):960-8. PubMed ID: 27091234
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.
Nishikawa A; Ishida T; Taketsuna M; Yoshiki F; Enomoto H
Clin Interv Aging; 2016; 11():913-25. PubMed ID: 27462147
[TBL] [Abstract][Full Text] [Related]
18. Osteosarcoma and teriparatide?
Harper KD; Krege JH; Marcus R; Mitlak BH
J Bone Miner Res; 2007 Feb; 22(2):334. PubMed ID: 17129179
[No Abstract] [Full Text] [Related]
19. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
20. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window.
Bilezikian JP
Curr Osteoporos Rep; 2008 Mar; 6(1):24-30. PubMed ID: 18430397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
